# Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection

> **NCT02134886** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (actual)

## Conditions studied

- HIV Infection
- Recurrent Non-Small Cell Lung Carcinoma
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT02134886
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** No Accrual
- **Last updated:** 2015-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02134886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02134886, "Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02134886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*